KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBT Margin (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed EBT Margin for 16 consecutive years, with 3.1% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 2580.0% year-over-year to 3.1%, compared with a TTM value of 14.98% through Dec 2025, down 401.0%, and an annual FY2025 reading of 14.98%, down 401.0% over the prior year.
  • EBT Margin was 3.1% for Q4 2025 at Biomarin Pharmaceutical, up from 3.39% in the prior quarter.
  • Across five years, EBT Margin topped out at 36.09% in Q2 2025 and bottomed at 14.8% in Q4 2021.
  • Average EBT Margin over 5 years is 8.94%, with a median of 6.85% recorded in 2023.
  • The sharpest move saw EBT Margin skyrocketed 2106bps in 2022, then tumbled -2580bps in 2025.
  • Year by year, EBT Margin stood at 14.8% in 2021, then soared by 78bps to 3.27% in 2022, then skyrocketed by 192bps to 2.99% in 2023, then skyrocketed by 659bps to 22.7% in 2024, then plummeted by -114bps to 3.1% in 2025.
  • Business Quant data shows EBT Margin for BMRN at 3.1% in Q4 2025, 3.39% in Q3 2025, and 36.09% in Q2 2025.